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Background: Patient outcomes have been compared on the basis of the profit status of the dialysis provider
(for-profit [FP] and not-for-profit [NFP]). In its annual report, United States Renal Data System (USRDS) provides
dialysis provider level death and hospitalization rates adjusted by age, race, sex, and dialysis vintage; however,
recent analyses have suggested that other variables impact these outcomes. Our current analysis of hospitalization
and mortality rates of hemodialysis patients included adjustments for those used by the USRDS plus other potential
confounders: facility geography (end-stage renal disease network), length of facility ownership, vascular access at
first dialysis session, and pre-dialysis nephrology care.
Methods: We performed a provider level, retrospective analysis of 2010 hospitalization and mortality rates among
US hemodialysis patients exclusively using USRDS sources. Crude and adjusted incidence rate ratios (IRRs) were
calculated using the 4 standard USRDS patient factors plus the 4 potential confounders noted above.
Results: The analysis included 366,011 and 34,029 patients treated at FP and NFP facilities, respectively. There were
statistical differences between the cohorts in geography, facility length of ownership, vascular access, and pre-dialysis
nephrology care (p < 0.001), as well as age (p < 0.01), race (p < 0.001), and vintage (p < 0.001), but not sex (p = 0.12).
When using standard USRDS adjustments, hospitalization and mortality rates for FP and NFP facilities were most
disparate, favoring the NFP facilities. Rates were most similar between providers when adjustments were made
for each of the 8 factors. With the FP IRR as the referent (1.0), the hospitalization IRR for NFP facilities was 1.00
(95% confidence interval [CI] 0.97-1.02; p = 0.69), while the NFP mortality IRR was 1.01 (95% CI 0.97-1.05; p = 0.64).
Conclusions: These data suggest there is no difference in mortality and hospitalization rates between FP and NFP
dialysis clinics when appropriate statistical adjustments are made.Background
Since the founding of National Medical Corporation, the
first for-profit dialysis chain, in the early 1970’s there has
been scrutiny of the level of care provided by commer-
cial dialysis companies. In fact, United States Renal Data
System (USRDS) analytic files have a flag identifying a
provider as either not-for-profit (NFP) or for-profit (FP)
in order to facilitate comparisons. Over the years, a
number of comparative analyses of FP versus NFP pro-
viders have been published [1-5]. Each year, the USRDS
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sex, and dialysis vintage [6]. More recently, it has been
observed that patients dialyzing with FP and NFP facil-
ities differ on the basis of other key patient and non-
patient factors—such as pre-dialysis nephrology care,
length of ownership for dialysis clinics, geography or lo-
cation of dialysis clinics, and vascular access at dialysis
initiation—that themselves are important determinants
of patient outcomes [1,7-14]. (Mahesh Krishnan, T
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prior published comparisons of outcomes between FP and
NFP facilities have biases that affect the results. With the
advent of sophisticated analytical techniques, more recent
provider-level analyses have attempted to account for con-
founding derived from differences that exist between dia-
lysis provided at FP versus NFP facilities [15].
The purpose of our current investigation was to
characterize case mix differences between FP and NFP
facilities and to estimate the associations of profit status
with mortality and hospitalization rates adjusted for tra-
ditional and non-traditional confounders so as to provide
less biased comparisons. In order to minimize ascertain-
ment bias, all study data were taken from USRDS Stand-
ard Analytical Files.
Methods
We performed a provider level, retrospective, observa-
tional analysis of hospitalization and mortality rates
among patients receiving hemodialysis at US dialysis fa-
cilities during 2010. Study data were taken from the
2010 USRDS Standard Analytical Files, which are avail-
able for analysis by request with associated data access
fees. In USRDS data, hospitalizations are identified from
Medicare Part A claims; therefore study inclusion was
limited to patients with Medicare Part A primary insur-
ance. The primary exposure of interest was dialysis facility
ownership status of each Medicare beneficiary’s treating
dialysis organization (ie, FP versus NFP). We calculated
the study outcomes according to FP and NFP center status
as rates expressed in hospitalizations per patient-year at
risk or deaths per 100 patient-years at-risk. Patients were
considered at-risk from 1 January 2010, or from the date
of ESRD enrollment during calendar year 2010, until
death or censoring for discontinuation of dialysis or
end of study period (31 December 2010). Patient hos-
pitalizations were drawn from the USRDS Institutional
Claims Files over the same period. Covariate data were
likewise derived from USRDS Standard Analytical Files.
Confounders considered were those variables commonly
used to adjust FP versus NFP comparisons (age, sex, race,
and dialysis vintage), as well as the ESRD network (as a
measure of geography), vascular access modality at first
dialysis treatment (central venous catheter [CVC], ar-
teriovenous fistula [AVF], arteriovenous graft [AVG]);
and pre-dialysis nephrology care (none; < 6 months, 6–12
months, > 12 months). Facility length of ownership was
another potential confounder considered for analysis
and was identified by examining each facility’s ascribed
organization over historically successive USRDS Facility
Reports (2007–2010).
The retrospective nature of this analysis made it ex-
empt from Institutional Review Board or Ethics Com-
mittee approval by the DaVita clinical operations team.Dialysis chains were described according to character-
istics of constituent patients at baseline (1 January 2010
or date of ESRD enrollment). Continuous patient vari-
ables are presented as means with standard deviations,
and compared using t-tests. Categorical variables were
described as frequencies and proportions and compared
using chi-square tests.
Crude incidence rates were calculated as the number
of events divided by the cumulative at-risk time. Mod-
eled rates and 95% confidence intervals (CIs) were based
on a negative binomial distribution due to observed
over-dispersion of Poisson models. Unadjusted incidence
rate ratios (IRRs) were estimated using exposure-only
negative binomial models. Adjusted IRRs were estimated
by sequential addition of covariate terms for baseline pa-
tient characteristics. Because first dialysis access type
and the flag indicating presence or absence of pre-
dialysis nephrology care were missing in some instances,
analyses adjusted for these factors were limited to pa-
tients with available data for the corresponding variable.
For each outcome, 5 unique regression models were fit.
In the first model, IRRs were adjusted as per the USRDS
analyses accounting for age, sex, race, and dialysis vin-
tage (Model 1, the USRDS standard model). For the sec-
ond model (Model 2), adjustments were made according
to Model 1 plus, geographic variations (ESRD network)
and facility length of ownership. In Model 3, the factors
adjusted in Model 2 were considered in addition to vas-
cular access at first dialysis. Model 4 included factors ad-
justed for in Model 2 plus pre-dialysis nephrology care.
Model 5 adjusted IRR calculations for all 8 of the factors
identified, including those for the USRDS standard model
(Model 1: age, sex, race, and dialysis vintage) plus ESRDS
network, length of facility ownership, vascular access at
first dialysis session, and pre-dialysis nephrology care.
In sensitivity analyses, missing data for pre-dialysis
nephrology care and vascular access type at first dialysis
were multiply imputed. Briefly, a joint multinomial
model was used to impute pre-dialysis nephrology care
(none; < 6 months, 6–12 months, > 12 months) and first
dialysis vascular access (AVF, AVG, CVC, other). Pre-
dialysis nephrology care and vascular access type were
mutually referential (ie, each predicted the other), and
also predicted on the basis of all covariates from Model
5, follow-up time (log transformed), and outcome indi-
cators (using the ICE procedure in Stata 10.0 MP). Five
bootstrap replicates were created. Outcome models were
fit using the MIM macro in Stata, which accounts for
multiplicity of observations across imputation set.
Results
Dialysis provider level demographic information for the
patient populations studied is provided in Table 1. The
mean age of patients treated at FP (N = 366,011) and
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62.3 years, respectively (p < 0.01). Mean dialysis vin-
tages were 2.6 and 2.7 years, respectively (p < 0.001).
Patients treated at FP facilities were more likely to be
white or black, and less likely to be Asian, Native
American, or Pacific Islander (p < 0.001). There was no
significant gender imbalance between FP and NFP fa-
cilities (p = 0.12).
Additional patient and dialysis center variables are pre-
sented in Table 2. Length of ownership was significantly
longer for NFP versus FP facilities. In the FP population
(N = 344,555), 94.1% of centers had an ownership of ≥
4 years compared to the 94.7% in the NFP population
NFP (N = 32,224; p < 0.001). Patients treated at NFP dialy-
sis facilities more frequently received their first dialysis
treatment with an AVF (19.7%) compared to those pa-
tients in the FP population (17.0%; p < 0.001), while in-
dividuals treated at FP dialysis facilities were more
frequently first dialyzed with a CVC in place (78.0%) than
NFP (75.6%; p < 0.001). Length of pre-dialysis nephrology
care received by patients also differed significantly
between study populations (p < 0.001). In NFP dialysis
facilities, 37.2% of patients received > 12 months of
pre-dialysis care compared to 30.4% of patients who di-
alyzed at FP centers. Patients receiving dialysis at FP
facilities went without any pre-dialysis nephrology care
more frequently than patients who dialyzed at NFP
facilities (30.3% versus 25.2%, respectively). Table 2 also
provides the number of facilities operating during the
year 2010 in each of the 18 USRDS ESRD networks.
Large disparities between the study populations related
to geographical distribution are demonstrated, particu-
larly in networks 10 (Illinois), 14 (Texas), 16 (Northwest




Continuous variables Mean Standard Devi
Age (years) 62.6 14.9
Vintage (years) 2.6 3.0
Categorical variables N Percent





Native American/Pacific Islander 4,390 1.2
Other 1,055 0.3
Unknown 93 0.03the proportion of clinics were heavily skewed towards
either FP or NFP status.
Provided in Table 3 are the hospitalization rates for the
FP and NFP populations. The crude unadjusted rate for
hospitalization was greater in the FP population (1.66 hos-
pitalizations per patient-year) than the NFP population
(1.59 hospitalizations per patient-year), corresponding to a
crude IRR for NFP of 0.95 (95% CI, 0.93-0.97) versus FP
facilities (IRR 1.0 referent). Estimates were nearly identical
when adjusted for the standard array of covariates (Model
1): IRR 0.96 (95% CI, 0.94-0.98). With sequential addition
of additional covariates, the protective association of NFP
was incrementally attenuated and no longer statistically
significant (Table 3, Figure 1). In the fully adjusted model
(Model 5), the NFP facility IRR for hospitalization was
1.00 (95% CI, 0.97-1.02; p = 0.69).
The crude mortality rate in the FP population was 23.1
deaths per 100 patient-years compared to 22.0 deaths per
100 patient-years in the NFP population (Table 4). The
unadjusted mortality IRR for the NFP group was found to
be 0.95 (95% CI, 0.92-0.98; p = 0.003). Again, estimates
were different when adjusted for age, race, sex, and vin-
tage: the NFP IRR was 0.96 (95% CI, 0.93-0.99; p = 0.009),
but were incrementally attenuated and lost statistical sig-
nificance upon additional covariate adjustments (Table 4,
Figure 2). In the fully adjusted model (Model 5), the NFP
IRR for death was 1.01 (95% CI, 0.97-1.05; p = 0.64).
Sensitivity analyses were conducted in which missing
values for pre-dialysis nephrology care and first vascu-
lar access type were imputed. In these analyses, there
was no statistically significant difference in the risk for
either hospitalization or death: fully adjusted IRRs for
NFP were 0.98 (95% CI, 0.97-1.00; p = 0.07) and 0.97




ation Mean Standard Deviation
62.3 15.2 < 0.01










Table 2 Comparison of additional potential confounding factors between for-profit and not-for-profit facilities
For-Profit N = 366,011 Not-For-Profit N = 34,029
P-value
N Percent N Percent
Facility length of ownership < 0.001
2 years 9,106 2.5 888 2.6
3 years 12,350 3.4 917 2.7
≥ 4 years 344,555 94.1 32,224 94.7
Vascular access at first treatment < 0.001
Catheter 208,016 78.0 18,182 75.6
Fistula 45,243 17.0 4,731 19.7
Graft 10,999 4.1 950 4.0
Other 2,605 1.0 174 0.7
Length of predialysis care < 0.001
> 12 months 76,905 30.4 8,915 37.2
6-12 months 62,785 24.8 5,868 24.4
< 6 months 36,510 14.4 3,165 13.2
None 76,662 30.3 6,050 25.2
ESRD network region < 0.001
1 11,036 3.0 629 1.9
2 15,084 4.1 3,339 9.8
3 8,373 2.3 662 2.0
4 16,002 4.4 1,565 4.6
5 21,864 6.0 791 2.3
6 37,720 10.3 4,804 14.1
7 26,229 7.2 1,110 3.3
8 22,549 6.2 3,220 9.5
9 28,838 7.9 2,259 6.6
10 16,832 4.6 76 0.2
11 18,171 5.0 3,223 9.5
12 12,401 3.4 2,290 6.7
13 17,128 4.7 614 1.8
14 39,625 10.8 284 0.8
15 17,924 4.9 2,201 6.5
16 8,122 2.2 2,963 8.7
17 16,108 4.4 3,330 9.8
18 32,005 8.7 669 2.0
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In the past, USRDS comparisons between FP and NFP
dialysis providers for rates of hospitalization and mortal-
ity have been adjusted for age, sex, race, and dialysis vin-
tage [6]. In our current analysis, the magnitude of the
differences between the FP and NFP populations for
these patient factors were clinically trivial, yet statistically
significant: age, 0.3 year; vintage, 0.1 year; sex, 0.4 percen-
tage point; and race, < 2 percentage points for any given
category. Here, rate estimates adjusted for these factors
(Model 1) are not substantively different from unadjustedestimates. Consistent with recent literature, we have
shown more substantive differences in pre-dialysis neph-
rology care (5–7 percentage points) [7,8], vascular access
at first dialysis (2.5 percentage points) [7,16], and geo-
graphic region [17,18]. These factors, though not under
the control of the dialysis facility, are potent determinants
of patient outcomes. Thus, considering these factors to-
gether with age, sex, race, and dialysis vintage renders a
potential effect of profit status on patient outcomes un-
detectable. Our results likely explain the lack of association
between profit status and patient outcomes identified in the
Table 3 Comparison of hospitalization rates between for-profit and not-for-profit facilities
Incidence Rate Ratio
For-Profit Not-For-Profit P-value
N = 366,011 N = 34,029
PtY = 290,995 PtY = 27,297
Hospitalization rates
Hospital admissions 482,922 43,362 –
Crude rate per year 1.66 1.59 –
Modeled rate per year (95% CI)a 1.83 (1.82-1.84) 1.74 (1.71-1.77) –
Unadjusted IRR (95% CI)a 1 (reference) 0.95 (0.93-0.97) < 0.001
Model 1 (standard model)a: IRR (95% CI) adjusted for age, race, sex, vintage [N = 400,040] 1 (reference) 0.96 (0.94-0.98) < 0.001
Model 2a: IRR (95% CI) standard model + ESRD network, facility LOO [N = 400,040] 1 (reference) 0.98 (0.96-1.00) 0.02
Model 3a: IRR (95% CI) standard model + ESRD network, facility LOO, first access [N = 290,900] 1 (reference) 0.99 (0.97-1.01) 0.25
Model 4a: IRR (95% CI) standard model + ESRD network, facility LOO, pre-dialysis nephrology care
[N = 276,680]
1 (reference) 1.00 (0.98-1.02) 0.89
Model 5a: IRR (95% CI) standard model + ESRD network, facility LOO, first access, pre-dialysis nephrology
care [N = 252,270]
1 (reference) 1.00 (0.97-1.02) 0.69
Abbreviations: CI, confidence interval; ESRD, end-stage renal disease; IRR, incident rate ratio; LOO, length of ownership; PtY, patient-years.
aNegative binomial model.
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lysis [15]. Instrumental variables analysis adjusts for both
measured and unmeasured confounding. The unmeasured
confounding in the previous study likely included the spe-
cific differences we identified in facility geography, length of
facility ownership, vascular access at first dialysis session,
and pre-dialysis nephrology care [15].
A dramatic finding of this study is the large disparity
between FP and NFP clinic geography within the US,
which is known to significantly impact patient mortality
[13]. While the variables of vascular access at first dialy-
sis session and pre-dialysis nephrology care were ad-
justed for in this study, clinic geography is likely to have
other important impacts on health care outcomes. For
example, there are fewer nephrologists available for con-
sultation in rural areas [19], and early pre-dialysis careFigure 1 Hospitalization incidence rate ratios at not-for-profit versus
LOO, length of ownership.with a specialist positively impacts dialysis patient sur-
vival [20,21], as well as affording educated decisions for
selection of modality and vascular access [22]. Currently
unpublished data demonstrate that the large FP US dia-
lysis organizations disproportionately serve rural and
high poverty urban areas compared to other providers,
[Fadi Almachraki et al., 2014 manuscript in preparation]
further confounding comparative analyses between large
and small providers and FP and NFP facilities.
Our results beg the question: why are these additional va-
riables confounding analyses of mortality and hospitalization
rates between clinic categories? One reason may be re-
ferral patterns of health care providers who directly in-
fluence where patients receive care. Health care referral
patterns are affected by dialysis clinic geography and arbi-
trary factors such as the availability of private or publicfor-profit facilities. Abbreviations: ESRD, end-stage renal disease;
Table 4 Comparison of mortality rates between for-profit and not-for-profit facilities
Incidence Rate Ratio
For-Profit Not-For-Profit P-value
N = 366,011 N = 34,029
PtY = 290,995 PtY = 27,297
Mortality rates
Deaths 59,611 5,366 –
Crude rate per 100 patient-years 20.5 19.7 –
Modeled rate per 100 patient-years (95% CI)a 23.1 (22.7-23.4) 22.0 (21.3-22.7) –
Unadjusted IRR (95% CI)a 1 (reference) 0.95 (0.92-0.98) 0.003
Model 1 (standard model)a: IRR (95% CI) adjusted for age, race, sex, vintage [N = 400,040] 1 (reference) 0.96 (0.93-0.99) 0.009
Model 2a: IRR (95% CI) standard model + ESRD network, facility LOO [N = 400,040] 1 (reference) 0.97 (0.94-1.00) 0.03
Model 3a: IRR (95% CI) standard model + ESRD network, facility LOO, first access [N = 290,900] 1 (reference) 0.98 (0.95-1.02) 0.40
Model 4a: IRR (95% CI) standard model + ESRD network, facility LOO, pre-dialysis nephrology care
[N = 276,680]
1 (reference) 1.01 (0.97-1.05) 0.52
Model 5a: IRR (95% CI) standard model + ESRD network, facility LOO, first access, pre-dialysis nephrology
care [N = 252,270]
1 (reference) 1.01 (0.97-1.05) 0.64
Abbreviations: CI, confidence interval; ESRD, end-stage renal disease; IRR, incident rate ratio; LOO, length of ownership; PtY, patient-years.
aNegative binomial model.
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Health care provider beliefs, insurance provider policies,
and institutional practices are all likely to impact whether
patients are referred for pre-dialysis care to nephrologists,
who—according to beliefs, policies, and practices-would
recommend patients for surgery to receive AVF placement
prior to dialysis initiation. Clinic geography, which in our
analysis was widely varied across FP and NPF providers,
probably affects patient outcomes, as isolated clinics in ei-
ther urban or rural locations may be the only available dia-
lysis facility in a given region, and patients have no choice
of provider to patronize. Moreover, NP and NFP dialysis or-
ganizations have fundamentally different risk tolerance to
drive growth by either de novo clinic development or acqui-
sition of existing dialysis clinics. Potential differences in ac-
ceptable economic risk are probably heavily influenced byFigure 2 Mortality incidence rate ratios at not-for-profit versus for-pr
length of ownership.geographic area, including the density of patients with
ESRD requiring dialysis treatment within a given area, and
the available facilities within the area. This “growth” vari-
able directly impacts length of clinic ownership, which we
have demonstrated as affecting estimates for hospitalization
and mortality rates.
In addition to varying economic risk tolerance, there are
probably real philosophical differences between FP and
NFP dialysis providers; however these differences are not
necessarily negative. For instance, there may be a percep-
tion that quality concessions can be used to maximize
profits. However, in actuality the opposite is true. The Cen-
ters for Medicare and Medicaid Services Quality Incentive
Program penalizes facilities up to 2% of all Medicare remu-
neration for failure to meet quality metrics [23], and publi-
cizes financial penalties levied on poor-performing dialysisofit facilities. Abbreviations: ESRD, end-stage renal disease; LOO,
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care. Moreover, considering that facility census is the chief
economic driver, any sacrifice in quality that leads to missed
treatments (eg, due to hospitalization), death, or transfer of
care away from the provider organization are economically
counter-productive. Furthermore, profit motives may spur
clinical innovations such CathAway [24], Incident Manage-
ment of Patients, Actions Centered on Treatment (IM-
PACT) [25], and RightStart [26], which positively affect
outcomes for hemodialysis patients. The integration of
ESRD patient care with other aspects of healthcare have
also been facilitated by the FP LDOs including surgical
centers for vascular access and endovascular care (Life-
Line, Ultracare), specialty pharmacies for dialysis patients
(DaVita Rx [27], Fresenius Rx) and patient-focused pro-
grams for diabetes disease management (Village Health
StepAhead). Although there are clear financial incentives
to such programs, all fundamentally benefit patient care.
While the FP category of dialysis providers in the US
is dominated by 2 LDOs, the NFP category is dominated
by one LDO, such that its business practices and history
alone influence the entire category. A post-hoc analysis
(data not shown) demonstrated that this single NFP
LDO had superior hospitalization and mortality rates to
FP centers, whereas the remainder of NFP centers col-
lectively performed inferiorly. Unknown factors, related
or possibly unrelated to the quality of care, may be driv-
ing the differences in outcomes between this one NFP
LDO and other NFP dialysis chains.
We recognize a limitation of this study is its observational
design, which can only measure associations between ex-
posure and the outcomes studied. Although we attempted
to adjust analyses for a robust vector of covariates that
characterizes salient differences between patient popula-
tions served by FP versus NFP dialysis organizations, we ac-
knowledge that there may be residual confounding on the
basis of variables not considered. However, it is unlikely
that a randomized trial allocating patients to FP versus NFP
centers will ever be conducted to definitively assess causal
effects.
Conclusions
It is our belief that these data demonstrate a need for
additional adjustments to be made to analytics comparing
rates of hospitalization and mortality between dialysis pro-
viders or units. Omission of these factors in analytic adjust-
ments can result in conclusions that may not accurately
reflect differences in patient outcomes. Since a randomized
prospective trial with regards to profit status of dialysis pa-
tients is impractical, we believe that the current study, in
addition to other emerging literature, demonstrates that no
difference exists in outcomes between dialysis providers
stratified by profit status. Furthermore we believe that some
heterogeneity exists in all provider types such that broadclassification of providers by a single profit status flag may
also create unintended and misleading results.
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